Stay updated on IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page.

Latest updates to the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedPublications section gains a new Clin Cancer Res. 2025 IPATHER article citation and a note that publications are automatically filled from PubMed.SummaryDifference0.2%

- Check17 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.2 with no changes to the study details or text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check24 days agoChange DetectedNotice about government funding and NIH operating status has been removed from the page. The study details, eligibility criteria, locations, and contacts remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check46 days agoChange DetectedNo significant changes detected between the two screenshots; the page continues to present the study details for NCT04253561 (Ipatasertib + Pertuzumab + Trastuzumab in HER2+ PI3KCA-mutant breast cancer).SummaryDifference0.3%

- Check67 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision.SummaryDifference2%

- Check75 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0 with three new identifiers added (0034620170641, 0034626395532).SummaryDifference0.0%

Stay in the know with updates to IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page.